daiichi sankyo

GHIT Fund Deepens Support For Schistosomiasis & Leishmaniasis

An additional US$11 million has been committed to developing diagnostics and drugs for neglected tropical diseases.

Daiichi Sankyo Sells Shares Of Sun Pharma

Rocked by FDA warnings and fines, Sun Pharma has been dropped by Japanese pharmaceutical giant Daiichi Sankyo.

Sun Pharma Acquires Ranbaxy To Form India’s Largest Pharma

The US$3.2 billion transaction will form the largest pharmaceutical company in India and the fifth largest specialty generics manufacturer in the world.

Astellas, Daiichi Sankyo To Share 400,000 Drug Compounds

Two of Japan's largest pharmaceutical firms will share their drug libraries, making 400,000 compounds available for high throughput sequencing.

Ranbaxy Fines: More Than Meets The Eye

Indian generics manufacturer Ranbaxy was recently slapped with fines by the U.S. FDA for the manufacturing and distribution of 'adulterated' drugs.

Japan Launches Public-Private Partnership To Fight Neglected Diseases

The Global Health Innovative Technology Fund, a new public-private partnership, is taking Japanese R&D to the global fight against infectious disease.

Daiichi Sankyo And NGM To Develop New Treatments For Diabetes

Daiichi Sankyo and NGM Biopharmaceuticals will collaborate to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

GSK And Daiichi Sankyo Joint Venture To Form Largest Vaccines Company In Japan

GlaxoSmithKline and Daiichi Sankyo Co. Ltd. have signed a joint venture agreement to form a vaccines company in Japan.

Hiroyuki Mano Wins Ninth Takamine Memorial Daiichi Sankyo Prize

Professor Hiroyuki Mano of Jichi Medical University has won the Ninth Takamine Memorial Daiichi Sankyo Prize.

Japan Approves Oral Factor Xa Inhibitor For Venous Thromboembolism

Daiichi Sankyo Co. has received its first marketing approval for LIXIANA® tablets by the Ministry of Health, Labor and Welfare in Japan.